Fintel reports that on January 26, 2026, Oppenheimer upgraded their outlook for Relay Therapeutics (NasdaqGM:RLAY) from Perform to Outperform.
Analyst Price Forecast Suggests 96.21% Upside
As of January 14, 2026, the average one-year price target for Relay Therapeutics is $14.89/share. The forecasts range from a low of $12.12 to a high of $19.95. The average price target represents an increase of 96.21% from its latest reported closing price of $7.59 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Relay Therapeutics is 65MM, an increase of 675.66%. The projected annual non-GAAP EPS is -2.68.
What is the Fund Sentiment?
There are 375 funds or institutions reporting positions in Relay Therapeutics. This is an decrease of 28 owner(s) or 6.95% in the last quarter. Average portfolio weight of all funds dedicated to RLAY is 0.08%, an increase of 6.63%. Total shares owned by institutions decreased in the last three months by 4.10% to 179,790K shares. 
The put/call ratio of RLAY is 0.12, indicating a bullish outlook.
What are Other Shareholders Doing?
Sb Investment Advisers holds 27,905K shares representing 16.10% ownership of the company. No change in the last quarter.
Commodore Capital holds 17,000K shares representing 9.81% ownership of the company. In its prior filing, the firm reported owning 13,350K shares , representing an increase of 21.47%. The firm increased its portfolio allocation in RLAY by 32.87% over the last quarter.
Point72 Asset Management holds 14,774K shares representing 8.52% ownership of the company. In its prior filing, the firm reported owning 13,446K shares , representing an increase of 8.99%. The firm increased its portfolio allocation in RLAY by 41.31% over the last quarter.
Casdin Capital holds 11,341K shares representing 6.54% ownership of the company. In its prior filing, the firm reported owning 11,399K shares , representing a decrease of 0.50%. The firm increased its portfolio allocation in RLAY by 37.45% over the last quarter.
Bellevue Group holds 8,346K shares representing 4.82% ownership of the company. In its prior filing, the firm reported owning 8,231K shares , representing an increase of 1.37%. The firm increased its portfolio allocation in RLAY by 44.21% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
